LANCASTER, PA — Emerald Advisers, in collaboration with F/m Investments, has introduced the F/m Emerald Life Sciences Innovation ETF (LFSC), now available on the Nasdaq Stock Market under the ticker LFSC. This new ETF aims to provide investors with access to cutting-edge companies in the life sciences sector, focusing on biotechnology, healthcare, and medical device advancements.
Stacey Sears, Senior Vice President and Portfolio Manager at Emerald, expressed excitement about the launch, stating, “We are excited to bring this ETF to market, offering investors access to some of the most cutting-edge developments in healthcare and biotechnology. We say ‘innovation starts small,’ as small-cap companies are often first-movers, particularly in sectors like gene therapies and medical diagnostics.”
The ETF is actively managed with a focus on small and mid-cap companies poised for breakthroughs in biotechnology, pharmaceuticals, and medical technology. Joseph W. Garner, Emerald’s Director of Research, noted the fund’s strategic approach: “LFSC leverages Emerald’s proprietary 10-Step Research Process, combining fundamental analysis with hands-on research to identify companies that we believe are at the forefront of life sciences innovation.”
Alexander Morris, CEO of F/m Investments, highlighted the ETF’s potential, saying, “The F/m Emerald Life Sciences Innovation ETF provides an opportunity for investors to tap into the transformative advancements taking place in healthcare and biotech. We’re proud to partner with Emerald to offer investors access to the dynamic growth potential of this crucial sector.”
The life sciences industry is undergoing rapid growth, driven by an aging population, increasing healthcare demand, and significant investments in biotechnology. With U.S. healthcare spending projected to rise significantly, LFSC offers diversified exposure to companies at the forefront of medical innovation, with a focus on long-term growth potential.
Scott Rehr, CEO of Emerald, emphasized the strategic importance of the ETF: “Emerald has a long history of identifying high-growth opportunities in emerging sectors. The launch of LFSC reflects our commitment to delivering innovative investment solutions that align with long-term growth trends.”
As Emerald Advisers and F/m Investments embark on this venture, both parties are confident that the F/m Emerald Life Sciences Innovation ETF will meet investors’ needs for innovative and growth-oriented investment opportunities in the evolving healthcare landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.